Amycretin Australia: Research Overview (2026)

The short answer

Amycretin is an investigational compound being developed by Novo Nordisk. It is described in the public literature as a unimolecular agonist, meaning a single molecule that acts at both the GLP-1 receptor and the amylin receptor. Both an oral formulation and a subcutaneous formulation have been reported in development. As of 2026 it is in clinical development and is not an approved product.

In Australia, amycretin is not approved by the Therapeutic Goods Administration (TGA) and is not entered on the Australian Register of Therapeutic Goods (ARTG). It is an experimental, investigational compound. NovaPeptides references amycretin for educational purposes only and supplies it strictly for laboratory research use, not for human or veterinary use.

What is amycretin?

Amycretin is a peptide-based investigational compound reported in Novo Nordisk's pipeline and in peer-reviewed and conference literature. It is characterised as a long-acting agonist at two separate receptor targets at once: the glucagon-like peptide-1 (GLP-1) receptor and the amylin receptor. Because a single molecule carries activity at both targets, it is often called a unimolecular or dual agonist.

A notable feature reported in the literature is that amycretin has been studied in both an oral form and a subcutaneous form. Having both routes explored within one development programme is relatively unusual and is one reason the compound has attracted research interest.

How amycretin is described in the literature

• A single-molecule (unimolecular) agonist
• Acts at the GLP-1 receptor and the amylin receptor
• Reported in both oral and subcutaneous formulations
• Developed by Novo Nordisk
• Currently investigational, not an approved product

The mechanism in plain terms

GLP-1 and amylin are two distinct signalling pathways that the body uses in the regulation of metabolism and appetite signalling. GLP-1 receptor agonists are a well-known class in the scientific literature, and amylin receptor agonists are a separate class. Amycretin is of research interest because it combines activity at both of these receptor systems within one molecular structure.

This single-molecule design is the defining characteristic researchers point to. Rather than combining two finished drugs, the two activities are engineered into one peptide. The scientific rationale discussed in the literature is around how a single molecule hitting two complementary pathways behaves pharmacologically compared to agents that act on only one pathway.

How amycretin differs from CagriSema

A common point of confusion is the difference between amycretin and CagriSema, because both involve GLP-1 and amylin pathways. The distinction is structural. CagriSema is a co-formulation: it combines two separate molecules, cagrilintide (an amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist), blended together into one product. Each molecule retains its own identity and acts on its own target.

Amycretin, by contrast, is a single molecule engineered to carry both GLP-1 and amylin receptor activity by itself. So where CagriSema is two molecules working side by side, amycretin is one molecule doing both jobs. This is the core conceptual difference researchers draw between the two.

Side-by-side framing

• CagriSema: two separate molecules (cagrilintide plus semaglutide) co-formulated together
• Amycretin: one single molecule acting at both GLP-1 and amylin receptors
• Semaglutide alone: a single-target GLP-1 receptor agonist
• Cagrilintide alone: a single-target amylin receptor agonist

Where amycretin sits in clinical development

Public statements from Novo Nordisk indicate that amycretin progressed through earlier-phase studies and that the company announced, in mid-2025, its intention to advance both the subcutaneous and oral formulations into phase 3 clinical development following end-of-phase 2 discussions with regulatory authorities. This reflects a compound that is well into clinical development rather than at an early laboratory stage.

It is important to read trial-stage information neutrally. Clinical development is a programme that continues over time, and progression into a later phase is not an approval. An investigational compound remains experimental until and unless a regulator grants marketing authorisation, which has not occurred in Australia for amycretin.

The Australian regulatory position

In Australia, medicines must generally be entered on the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully supplied as therapeutic goods. The ARTG is maintained by the Therapeutic Goods Administration (TGA) and lists products that have been assessed and approved for supply.

Amycretin is not approved by the TGA and is not on the ARTG. It is an investigational compound that has not received Australian marketing authorisation. For that reason, within Australia it is appropriately handled only as a research chemical in a controlled laboratory setting. NovaPeptides supplies amycretin strictly for laboratory research use only, not for human use, not for veterinary use, and not for self-administration.

What research use only means here

Research use only means a compound is intended solely for laboratory and scientific investigation by qualified researchers in an appropriate setting. It is not supplied as a medicine, a supplement, or a consumer product, and it is not intended for use in or on the human body or in animals.

NovaPeptides provides amycretin and related compounds under this framing. Nothing on this page should be read as encouragement to use amycretin in any living subject, nor as a dosing instruction, protocol, or reconstitution guide. We deliberately do not publish any such material for investigational compounds.

Our position in short

• Supplied for laboratory research use only
• Not for human or veterinary use
• No dosing, protocols, or preparation instructions provided
• No therapeutic or efficacy claims made
• Handled consistently with its investigational status

Summary

Amycretin is a single-molecule GLP-1 and amylin receptor agonist under clinical development by Novo Nordisk, with both oral and subcutaneous formulations reported. It differs from CagriSema in that CagriSema co-formulates two separate molecules, cagrilintide and semaglutide, whereas amycretin is one molecule acting at both targets. It is investigational, not TGA-approved, and not on the ARTG. NovaPeptides references it for education only and supplies it strictly for laboratory research use.

If you are researching this space, the sensible approach is to rely on primary scientific sources and official regulatory registers, and to treat all investigational compounds as experimental. This page is general information only and is not legal or medical advice.

Frequently asked questions